CARsgen Therapeutics Holdings Ltd
HKEX:2171

Watchlist Manager
CARsgen Therapeutics Holdings Ltd Logo
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Watchlist
Price: 15.98 HKD 4.72% Market Closed
Market Cap: 9.2B HKD
CARsgen Therapeutics Holdings Ltd
/
Income Statement
/
Revenue

CARsgen Therapeutics Holdings Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CARsgen Therapeutics Holdings Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Revenue
¥39.4m
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Revenue
¥17.4B
CAGR 3-Years
102%
CAGR 5-Years
68%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Revenue
¥9.4B
CAGR 3-Years
30%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Revenue
¥2.1B
CAGR 3-Years
111%
CAGR 5-Years
97%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Revenue
¥2.2B
CAGR 3-Years
-27%
CAGR 5-Years
14%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Revenue
¥1.9B
CAGR 3-Years
291%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

CARsgen Therapeutics Holdings Ltd
Glance View

Market Cap
9.1B HKD
Industry
Biotechnology

CARsgen Therapeutics Holdings Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of CAR-T cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 573 full-time employees. The company went IPO on 2021-06-18. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The firm have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The firm conducts its businesses in China and the United States.

Intrinsic Value
9.31 HKD
Overvaluation 42%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is CARsgen Therapeutics Holdings Ltd's Revenue?
Revenue
39.4m CNY

Based on the financial report for Dec 31, 2024, CARsgen Therapeutics Holdings Ltd's Revenue amounts to 39.4m CNY.

What is CARsgen Therapeutics Holdings Ltd's Revenue growth rate?
Revenue CAGR 3Y
15%

The average annual Revenue growth rates for CARsgen Therapeutics Holdings Ltd have been 15% over the past three years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 250,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.